| Followers | 1 |
| Posts | 110 |
| Boards Moderated | 0 |
| Alias Born | 11/30/2006 |
Wednesday, May 23, 2007 1:43:56 PM
Your chance of going to 44 cents is as good as "44" Henry Aaron being at the ball park when Bonds beats his record. Dorb is dead money.
Recent SNGX News
- SNGX Phase 3 Trial Halted — HyBryte Setback Puts Strategy in Question • IH Market News • 04/28/2026 03:06:46 PM
- SNGX Phase 3 Trial Halted on HyBryte • IH Market News • 04/28/2026 03:06:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 11:30:13 AM
- Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma • PR Newswire (US) • 04/28/2026 11:30:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/03/2026 04:15:15 AM
- Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy • PR Newswire (US) • 04/02/2026 11:30:00 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:13:29 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:11:25 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:09:30 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:08:14 PM
- Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results • PR Newswire (US) • 03/31/2026 11:30:00 AM
- Soligenix secures EU orphan drug designation for Behçet’s disease therapy • IH Market News • 03/26/2026 02:15:07 PM
- Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease • PR Newswire (US) • 03/26/2026 11:30:00 AM
- HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 • PR Newswire (US) • 03/23/2026 11:30:00 AM
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. • GlobeNewswire Inc. • 03/19/2026 12:00:00 PM
- Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" • PR Newswire (US) • 03/19/2026 11:30:00 AM
- Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency • PR Newswire (US) • 03/10/2026 11:30:00 AM
- Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease • PR Newswire (US) • 02/26/2026 12:30:00 PM
- Soligenix to Present at BIO Investment & Growth Summit • PR Newswire (US) • 02/24/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 09:05:19 PM
- Soligenix Details Recent Progress and Upcoming Milestones • PR Newswire (US) • 02/12/2026 12:30:00 PM
